For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
Documents
Released N-Glycan Analysis of Infliximab-dyyb including Sialylated Glycans using a bioZen 2.6 μm Glycan Column
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a bioZen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Released N-Glycan Analysis of Infliximab-dyyb including Sialylated Glycans using a bioZen 2.6 μm Glycan Column
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a bioZen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Document Type:
Technical Notes
Separation Modes:
HILIC